Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women

Circulation

Volumn 106, Issue 10, 2002, Pages 1224-1228

  Decensi, Andrea ^a   Omodei, Umberto ^a   Robertson, Chris ^a   Bonanni, Bernardo ^a   Guerrieri Gonzaga, Aliana ^a   Ramazzotto, Francesca ^a   Johansson, Harriet ^a   Mora, Serena ^a   Sandri, Maria Teresa ^a   Cazzaniga, Massimiliano ^a   Franchi, Massimo ^a   Pecorelli, Sergio ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Coronary disease; Hormones; Inflammation; Prevention; Risk factors

Indexed keywords

ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CONJUGATED ESTROGEN; ESTRADIOL; FENRETINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; MEDROXYPROGESTERONE ACETATE; PLACEBO; RETINOID;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; C-REACTIVE PROTEIN; CORONARY DISEASE; DERMIS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; FENRETINIDE; HUMANS; KINETICS; MIDDLE AGED; POSTMENOPAUSE; RISK FACTORS;

EID: 0037015287     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000028463.74880.EA     Document Type: Article

References (32)

1. Postmenopausal hormone therapy and mortality
2. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/Progestin Replacement Study (HERS) Research Group
3. Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study, a prospective, observational study
4. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
5. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study
6. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomized, controlled trial
7. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease
8. Association of fibrinogen. C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies
9. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
10. The protective effects of estrogen on the cardiovascular system
11. Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss
12. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer
13. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients
14. Transformations, means, and confidence intervals
15. Some examples of regression towards the mean
16. Least median of squares regression
17. High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease
18. Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women
19. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women
20. Emerging delivery systems for estrogen replacement: Aspects of transdermal and oral delivery
21. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women
22. Structure and function of the pentraxins
23. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management
24. C-reactive protein: Linking inflammation to cardiovascular complications
25. Elevated C-reactive protein levels in overweight and obese adults
26. Effect of body mass on the association between estrogen replacement therapy and mortality among elderly US women
27. C-reactive protein and hormone replacement therapy
28. Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes
29. C-reactive protein, interleukin-6, and risk of developing type 2 diabetes mellitus
30. Hepatocyte growth factor and retinoic acid exert opposite effects on synthesis of type 1 and type 2 acute phase proteins in rat hepatoma cells
31. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study
32. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: The Heart and Estrogen/Progestin Replacement Study